The Federal Government of Nigeria has launched the Innovative Cancer Medicine (ICM) Demonstration Study, a historic program providing advanced, free immunotherapy treatment for Nigerian patients battling metastatic colorectal cancer. Launched at the National Hospital Abuja on Tuesday, this is the first initiative of its kind in Sub-Saharan Africa, aiming to improve access to lifesaving cancer care.
In an 18-month program, 30 eligible patients nationwide will receive cutting-edge immunotherapy, including free diagnostics, follow-ups, and support, thanks to collaboration between the Federal Ministry of Health, Clinton Health Access Initiative, Parker Institute, Bristol Myers Squibb, Roche, and others. Minister of State for Health, Dr. Iziaq Salako, emphasized that the initiative reflects President Bola Tinubu’s commitment to reducing medical tourism and revolutionizing cancer treatment in Nigeria.
Colorectal cancer is increasingly aggressive in Nigeria, with over 5,900 annual deaths, often due to late diagnosis and limited access to modern treatments. The program also features real-time monitoring of patients to better understand treatment outcomes and side effects, while building Nigeria’s capacity in cancer diagnostics.
Cancer experts call this a turning point, heralding a new era of equitable, local access to innovative cancer medicines. It’s a bold step toward health justice and hope for many Nigerians.
Leave a comment